The last webinar in this four-part series elaborates on the value of nanoparticle tracking analysis (NTA) to the development of vaccines, including vaccine characterization of virus-like particles (VLPs) – such as those being developed as vaccines to COVID19.
More than a simple particle size analysis, the ability to rapidly make total (not just infective) particle concentration measurements is essential for vaccine developers looking to optimize the purity and shelf-life of their product.
NTA allows you to visualize and size all particles in the preparation, generating important information about nano-particle content. Furthermore, NTA can delivers this data in a shorter time than TCID50 or plaque assays. For instance, the presence of larger particles could represent either non-viral cell debris from the cell culture process or aggregates of virus particles containing many individual virions. In either case, such aggregates/contaminants represent a possible problem to the manufacturer. In this you will see how the Malvern Panalytical NanoSight helps vaccine developers devise a solution.
Ronald Soriano - Field Application Scientist - BioSciences Sector
Agnieszka Siupa - Product Manager - Nano Materials
- Who should attend?
- Scientists and project leaders in industry and academia working on the discovery and development of protein-based vaccines and therapeutics.